Paraskevas George P
2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
1st Department of Neurology, School of Medicine, Neurochemistry and Biological Markers Unit, "Eginition" Hospital, 11528 Athens, Greece.
Brain Sci. 2022 May 11;12(5):627. doi: 10.3390/brainsci12050627.
Over the course of the last 20 years, cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD), including amyloid beta peptide with 42 amino acids (Aβ), total tau protein (τ), and tau protein phosphorylated at a threonine residue at position 181 (τ), have become a useful tool for the recognition and diagnosis of AD, even in early or atypical clinical presentations and in the presymptomatic stage of the disease [...].
在过去20年中，用于阿尔茨海默病（AD）的脑脊液（CSF）生物标志物，包括42个氨基酸的淀粉样β肽（Aβ）、总tau蛋白（τ）以及在第181位苏氨酸残基处磷酸化的tau蛋白（P-tau），已成为AD识别和诊断的有用工具，即使在早期或非典型临床表现以及疾病的症状前阶段也是如此[...]。
